PubRank

Jorge A Tavel

Author PubWeight™ 16.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 What are biomarkers? Curr Opin HIV AIDS 2010 1.80
2 Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 2007 1.52
3 Regulatory approvals in a large multinational clinical trial: the ESPRIT experience. Control Clin Trials 2002 1.37
4 Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012 1.31
5 Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 2005 1.17
6 The quality of informed consent in a clinical research study in Thailand. IRB 2005 1.13
7 CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis 2004 1.10
8 Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004 1.06
9 CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis 2008 0.99
10 A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study. PLoS Clin Trials 2006 0.95
11 Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses 2006 0.94
12 Analysis of generic nevirapine products in developing countries. JAMA 2003 0.88
13 Informed consent: practices and views of investigators in a multinational clinical trial. IRB 2006 0.83
14 Antiretroviral drug content in products from developing countries. Clin Infect Dis 2004 0.82
15 Protocol Development Program: A Novel Approach to Overcoming Barriers to Clinical Research. Monitor (Assoc Clin Pharmacol) 2013 0.77
16 Therapeutic use of interleukin-2 in HIV-infected patients. Curr Opin Pharmacol 2002 0.75